Introduction {#Sec1}
============

Bronchodilators, including long-acting β~2~-agonists (LABAs), are central to the symptom management of chronic obstructive pulmonary disease (COPD).^[@CR1]^ The twice-daily (BID) inhaled LABAs formoterol and salmeterol have been available for the treatment of COPD since the late 1990s and effectively improve lung function, symptoms of breathlessness and quality of life.^[@CR2]^ Of the two agents, formoterol (12 µg BID) also has the benefit of a faster onset of action.^[@CR3]^ Owing to the extensive experience with these established agents, they have well-defined safety and tolerability profiles that have been used as reference for β~2~-agonist class effects when evaluating other LABAs.^[@CR4],[@CR5]^

Inhaled LABAs are generally well tolerated but have acknowledged class side effects, including palpitations, headache, nasopharyngitis and tremor.^[@CR1],[@CR6]^ There are also potential cardiovascular risks such as arrhythmia and myocardial ischaemia associated with LABAs, particularly in patients with concomitant cardiac disorders, which are common co-morbidities in patients with COPD.^[@CR7]^

Olodaterol is a novel once-daily (QD) LABA that has recently been approved and is available to clinicians via the Respimat^®^ device (Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany) (5 µg QD).^[@CR8]^ Given that olodaterol has only been available since mid-2014, post-marketing experience is currently limited; however, long-term safety data for olodaterol (5 and 10 µg QD) are available from a large clinical trial programme.^[@CR8],[@CR9]^ We conducted an analysis to specifically assess the safety profile of the approved and marketed dose of olodaterol (5 µg QD) in comparison to formoterol (12 µg BID). This analysis goes beyond a standard safety review by considering specific adverse events (AEs) associated with the class, as well as those included in the label for formoterol and olodaterol, to provide clinicians with a clear understanding of its safety profile and place olodaterol into context with other LABAs. The pooled safety analysis was pre-specified but without incidence rates, and additional grouped terms were added. The higher dose of olodaterol in these studies (10 µg) has not been discussed in this paper.

Results {#Sec2}
=======

A total of 1379 patients were included in this analysis: 460 randomised to placebo, 459 to olodaterol 5 µg and 460 to formoterol 12 µg. In general, the treatment groups were well balanced with respect to demographic and baseline patient characteristics (Table [1](#Tab1){ref-type="table"}), although the placebo group had a slightly larger proportion of patients with a COPD severity of Global Initiative for Chronic Obstructive Lung Disease (GOLD) 4 (10.0 versus 6.8% in the olodaterol group and 8.3% in the formoterol group). A substantial proportion of patients in each group had cardiac (18.9, 19.0 and 20.0%, respectively) or vascular (42.0, 41.2 and 43.7%, respectively) co-morbidities, reflecting the severity of COPD in this study patient population.Table 1Demographic and baseline patient characteristics (treated population)CharacteristicsPlacebo (*n* = 460)Olodaterol 5 µg (*n* = 459)Formoterol 12 µg (*n* = 460)Male, *n* (%)375 (81.5)364 (79.3)371 (80.7)Mean (SD) age, years63.9 (8.1)63.7 (8.9)64.9 (8.4)Smoking status, *n* (%)Ex-smoker301 (65.4)303 (66.0)305 (66.3)Current smoker159 (34.6)156 (34.0)155 (33.7)Mean (SD) smoking history, pack-years43.7 (25.0)43.0 (25.0)45.1 (26.0)Mean (SD) BMI (kg/m^2^)25.2 (5.2)25.3 (5.7)24.9 (5.2)Co-morbidities, *n* (%)Cardiac87 (18.9)87 (19.0)92 (20.0)Vascular193 (42.0)189 (41.2)201 (43.7)GOLD, *n* (%)1 (≥30%)1 (0.2)2 (0.4)3 (0.7)2 (50--\<80%)242 (52.6)255 (55.6)247 (53.7)3 (30--\<50%)171 (37.2)171 (37.3)172 (37.4)4 (\<30%)46 (10.0)31 (6.8)38 (8.3)Baseline pulmonary medication, *n* (%)Any pulmonary medication377 (82.0)391 (85.2)385 (83.7)SAMA136 (29.6)144 (31.4)133 (28.9)LAMA118 (25.7)117 (25.5)117 (25.4)SABA217 (47.2)218 (47.5)220 (47.8)LABA170 (37.0)168 (36.6)173 (37.6)Oral β-adrenergics4 (0.9)6 (1.3)2 (0.4)Leukotriene receptor antagonists11 (2.4)9 (2.0)2 (0.4)Mucolytics31 (6.7)31 (6.8)34 (7.4)Oxygen4 (0.9)0 (0.0)1 (0.2)ICS227 (49.3)222 (48.4)210 (45.7)Oral steroids7 (1.5)12 (2.6)5 (1.1)Xanthines78 (17.0)88 (19.2)80 (17.4)*SD* standard deviation, *BMI* body mass index, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *SAMA* short-acting muscarinic antagonist, *LAMA* long-acting muscarinic antagonist, *SABA* short-acting β-agonist, *LABA* long-acting β~2~-agonist, *ICS* inhaled corticosteroid

A greater proportion of patients discontinued treatment in the placebo group (23.5%) than the olodaterol 5 µg (15.9%) or formoterol 12 µg (18.0%) groups. A Kaplan--Meier analysis of time to discontinuation for any reason showed that the probability of discontinuation was significantly higher with placebo than olodaterol (*P* = 0.0013) and formoterol (*P* = 0.0180) throughout the study (Fig. [1](#Fig1){ref-type="fig"}). Discontinuations were similar between olodaterol and formoterol, with the Kaplan--Meier curve for time to discontinuation for olodaterol slightly below the one for formoterol over the whole observational period.Fig. 1Probability of discontinuation with placebo, olodaterol and formoterol. Cox regression analysis shows a significant difference from placebo for olodaterol 5 μg (*P* = 0.0013) and for formoterol treatment (*P* = 0.0180)

Summary of safety outcomes {#Sec3}
--------------------------

Patients with any AE were reported at 70.9, 71.7 and 69.1% in the placebo, olodaterol and formoterol groups, respectively. The incidence of serious AEs was slightly lower in the olodaterol and formoterol groups than with placebo. Ten patients in each group (2.2%) experienced fatal AEs. The incidence of AEs leading to discontinuation was lowest in the olodaterol 5 µg group (Fig. [2](#Fig2){ref-type="fig"}). The incidence of investigator-defined drug-related AEs was lower in the olodaterol 5 µg group (6.1%) than the placebo and formoterol 12 µg groups (9.1 and 11.1%, respectively).Fig. 2Overall incidence of adverse events (AEs)

Cardiovascular AEs {#Sec4}
------------------

The crude incidences of arrhythmia and myocardial ischaemia events were lower in the olodaterol 5 µg group than the placebo and formoterol 12 µg groups (Table [2](#Tab2){ref-type="table"}). Crude incidence of the combined torsade de pointes/QT prolongation Standardised MedDRA Query (SMQ) was five patients (1.1%) in each group. All cases were QT prolongation reported as an AE in any of the frequently repeated electrocardiogram study measurements; there was no occurrence of Torsades de pointes arrhythmia in any of the treatment groups.Table 2Incidence of cardiovascular, general and administration-related AEs (formoterol-labelled β~2~-agonist class side effects)AE, *n* (%)PlaceboOlodaterol 5 µgFormoterol 12 µg(*n* = 460)(*n* = 459)(*n* = 460)CardiovascularTachyarrhythmias (including extrasystoles)16 (3.5)10 (2.2)15 (3.3)Supraventricular (including atrial fibrillation)12 (2.6)5 (1.1)10 (2.2)Ventricular6 (1.3)5 (1.1)9 (2.0)Torsade de pointes/QT prolongation5 (1.1)5 (1.1)5 (1.1)Ischaemic heart disease12 (2.6)4 (0.9)7 (1.5)Myocardial infarction3 (0.7)1 (0.2)4 (0.9)Other ischaemic heart disease (non-infarction)9 (2.0)3 (0.7)3 (0.7)Hypotension1 (0.2)0 (0.0)2 (0.4)Hypertension16 (3.5)14 (3.1)10 (2.2)Palpitations8 (1.7)4 (0.9)10 (2.2)Peripheral oedema6 (1.3)8 (1.7)5 (1.1)Respiratory and administration relatedCough23 (5.0)13 (2.8)27 (5.9)Bronchospasm1 (0.2)0 (0.0)2 (0.4)Nasopharyngitis37 (8.0)59 (12.9)46 (10.0)Throat and other application-site irritation52 (11.3)69 (15.0)58 (12.6)GastrointestinalNausea7 (1.5)4 (0.9)3 (0.7)Dry mouth6 (1.3)7 (1.5)5 (1.1)MetabolismHypokalaemia1 (0.2)0 (0.0)0 (0.0)Hyperglycaemia/new-onset diabetes mellitus6 (1.3)7 (1.5)4 (0.9)MusculoskeletalArthralgia/myalgia/muscle weakness46 (10.0)50 (10.9)52 (11.3)Muscle spasm6 (1.3)8 (1.7)10 (2.2)Nervous systemDizziness11 (2.4)10 (2.2)10 (2.2)Tremor1 (0.2)2 (0.4)3 (0.7)Headache18 (3.9)16 (3.5)16 (3.5)PsychiatricNervousness1 (0.2)0 (0.0)0 (0.0)Restlessness/agitation1 (0.2)0 (0.0)1 (0.2)Anxiety3 (0.7)3 (0.7)1 (0.2)Insomnia1 (0.2)5 (1.1)3 (0.7)*AE* adverse event

The majority of exposure-adjusted incidence rate ratios (RRs) for the cardiovascular AE groups (including tachyarrhythmia and ischaemic heart disease) were lower with olodaterol compared to formoterol. However, differences were not statistically significant since the 95% confidence intervals (CIs) included 1.0 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot showing the exposure-adjusted rate and ratio for adverse events (AEs) of interest comparing olodaterol 5 µg with formoterol 12 µg. *CI* confidence interval

### General AEs and those associated with drug administration {#Sec5}

Overall, the crude incidences of other AE groups and those associated with drug administration were similar across the three treatment arms (Table [2](#Tab2){ref-type="table"}). The crude incidences of nasopharyngitis and throat and other application-site irritation were higher in the olodaterol 5 µg group (12.9 and 15.0%, respectively) than placebo (8.0 and 11.3%, respectively) and the formoterol 12 µg group (10.0 and 12.6%, respectively). The crude incidence of cough was lower with olodaterol (2.8%) than placebo (5.0%) and formoterol (5.9%).

The extent of exposure-adjusted RRs was in line with the observed crude incidence differences comparing olodaterol 5 µg to formoterol 12 µg. Olodaterol 5 µg was associated with numerically higher RRs of nasopharyngitis, throat and other application-site irritation, metabolism and psychiatric disorders (Fig. [3](#Fig3){ref-type="fig"}). Formoterol was associated with numerically higher RRs for cough, musculoskeletal, gastrointestinal and nervous system disorders. However, with the exception of cough (single MedDRA Preferred Term) and metabolism and nutrition disorders (collection of AEs in MedDRA System Organ Class), the 95% CIs for RRs of AEs between olodaterol and formoterol included 1.0 (i.e., were not statistically significant). There were low incidence rates for metabolic and nutrition disorders System Organ Class (mainly hypoglycaemia) with no substantial difference in the crude incidence for olodaterol or formoterol compared to placebo (Table [2](#Tab2){ref-type="table"}).

### Rescue medication {#Sec6}

Throughout the 48-week study period, patients receiving olodaterol 5 µg or formoterol 12 µg took significantly less daytime and night-time rescue medication than those receiving placebo (*P* \< 0.05). At Week 48, the weekly mean (standard error \[SE\]) number of puffs during the daytime was 1.322 (0.068), 1.053 (0.069) and 1.062 (0.069) with placebo, olodaterol 5 µg and formoterol 12 µg, respectively. The common baseline mean (SE) was 1.221 (0.039). For night-time rescue medication use, the weekly mean (SE) number of puffs was 2.023 (0.093), 1.492 (0.093) and 1.582 (0.093) with placebo, olodaterol 5 µg and formoterol 12 µg, respectively. The common baseline mean (SE) was 1.943 (0.053).

There were no relevant differences between the active treatment arms in rescue medication usage.

Discussion {#Sec7}
==========

Main findings {#Sec8}
-------------

This analysis of pooled data from two replicate, 48-week, phase III studies comparing olodaterol 5 µg QD with formoterol 12 µg BID or placebo in patients with moderate to very severe COPD (GOLD 2--4) showed that the overall incidence and types of most frequent AEs were similar in the olodaterol, placebo and formoterol groups. Nasopharyngitis, which is a known side effect of Striverdi^®^ Respimat^®^, occurred more frequently with olodaterol 5 µg than placebo.^[@CR8]^ Importantly, cardiovascular events occurred infrequently and generally with a similar or lower incidence with olodaterol 5 µg than placebo or formoterol 12 µg. This provides reassurance of the cardiovascular safety of olodaterol among the β~2~-agonist class in COPD treatment.

Interpretation of findings in relation to previously published work {#Sec9}
-------------------------------------------------------------------

Our analysis considered AEs typically associated with the inhaled β~2~-agonist class. The data originate from randomised controlled studies in which study medication was added on to existing background treatment across all groups, allowing the effect of the maintenance treatment LABA to be tested on top of a realistic COPD background therapy. The fact that there was no substantial difference with olodaterol and placebo in the incidence of AEs supports the acceptable general safety profile of this medication. The lack of any substantial difference between active treatments and placebo may have been influenced, however, by rescue medication usage; throughout the course of the study, the use of rescue medication (salbutamol) was higher in the placebo group than the active treatment arms, increasing patient exposure to the inherent β~2~-agonist risks.

The direct comparison of exposure-adjusted AE incidences between the olodaterol and formoterol groups indicated that both drugs have a similar safety profile overall. The safety profile of olodaterol in this analysis also appears similar to that reported for the LABAs indacaterol^[@CR5],[@CR10]^ and vilanterol^[@CR11]^ in patients with COPD. Donohue et al. reported that the most common AEs associated with indacaterol were worsening of COPD, nasopharyngitis and headache, and that there was no increase in the incidence of major adverse cardiovascular events with indacaterol versus placebo (0.69--1.10% versus 1.44%).^[@CR10]^ In an analysis of the cardiovascular and cerebrovascular safety profiles in patients with COPD, indacaterol was similar to formoterol, salmeterol, tiotropium and placebo.^[@CR5]^

Strengths and limitations of this study {#Sec10}
---------------------------------------

Co-morbidities are common in patients with COPD, including cardiac, metabolic, psychiatric, neurological and musculoskeletal disorders,^[@CR12]^ and this was indeed the case in our study. Therefore, it is difficult to establish a causal drug relationship to specific AEs when the population is at high risk of such events merely from their pre-existing diseases. Consequently, this analysis included all reported AEs irrespective of the study investigators' assessment of causality. For information, the incidence of drug-related AEs as detailed by the study investigators was low and not substantially different for olodaterol, placebo and formoterol (6.1, 9.1 and 11.1%, respectively).

Patient selection and treatment exposure in these studies were close to real-world data. Given the fact that large, long-term, blinded, randomised controlled trials are extremely difficult and expensive to conduct in COPD, a 1-year observation may not be long enough to detect very rare AEs. This is, however, usually the domain of post-marketing pharmacovigilance and not in scope of an everyday safety profile comparison. Overall, the nature and frequency of events reported in our studies were consistent with the disease under study and thus confirmed that olodaterol 5 µg QD has an acceptable safety and tolerability profile in patients with moderate to severe COPD, similar to that of the well-established LABA formoterol 12 µg BID.

Implications for future research, policy and practice {#Sec11}
-----------------------------------------------------

These safety profiling data add support to the previously published data with olodaterol.^[@CR9]^ However, as olodaterol is relatively new to the market (as with other once-daily LABAs), continued assessment will be required to ensure that its safety profile remains clearly defined.

Conclusions {#Sec12}
===========

Olodaterol 5 µg QD via Respimat^®^ was well tolerated over 48 weeks, with a typical β~2~-agonist safety profile comparable to formoterol 12 µg BID dry powder inhalation. The tolerability is also supported by the lowest discontinuation rate for olodaterol among all treatments. Based on blinded, randomised, parallel-group, placebo-controlled and formoterol-controlled, long-term clinical data, the incidence of AEs was similar with olodaterol 5 µg QD for serious AEs and cardiovascular AEs compared with formoterol 12 µg BID. Mortality was low and similar across all treatment groups (approximately 2.2%, which is a usual mortality rate over 1 year in a COPD population). These data give reassuring information about the safety of olodaterol as a LABA option in moderate to severe COPD maintenance treatment. The data from this analysis suggest that olodaterol is an adequate alternative to formoterol for COPD maintenance treatment.

Methods {#Sec13}
=======

This analysis included pooled data from two replicate, multicentre, double-blind, phase III studies of olodaterol (5 µg QD and 10 µg QD via Respimat^®^) compared to formoterol (12 µg BID dry powder inhalation) or placebo over 48 weeks (1222.13, NCT00793624; 1222.14, NCT00796653). Both devices (the olodaterol Respimat^®^ and the formoterol dry powder inhaler) were used together with the respective placebo device (double-dummy administration). The blinded formoterol study medication contained Foradil^®^.^[@CR13]^ The studies included patients with moderate to very severe COPD (GOLD 2--4) who were aged ≥40 years and were current or ex-smokers (with a smoking history \>10 pack-years). Patients with a history of asthma were excluded. With the exception of LABAs, patients continued with their existing COPD maintenance treatment, including short-acting muscarinic antagonists, long-acting muscarinic antagonists, corticosteroids and xanthines. All patients were provided with salbutamol as rescue medication. Full details of the study methodology have been published elsewhere.^[@CR14]^ In total across the two studies, 1838 patients were randomised to treatment (225 to placebo, 227 to olodaterol 5 µg, 225 to olodaterol 10 µg and 227 to formoterol 12 µg in study 1222.13; 235 to placebo, 232 to olodaterol 5 µg, 234 to olodaterol 10 µg and 233 to formoterol 12 µg in study 1222.14). This analysis focuses on the licensed dose of olodaterol (5 µg QD via Respimat^®^).

After a baseline visit, patients attended study visits following 2, 6, 12, 18, 24, 32, 40 and 48 weeks of treatment. AEs were recorded throughout the study, irrespective of investigator-reported causality.

Ethics {#Sec14}
------

The studies were performed in accordance with the Declaration of Helsinki, International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice and local regulations. The protocols were approved by the authorities and ethics committees of the respective institutions, and signed informed consent was obtained from all patients.

Selection of outcomes {#Sec15}
---------------------

Outcomes for comparing olodaterol with formoterol in this analysis were selected based on the typical β~2~-agonist class side effects, as exemplified by the formoterol (Foradil^®^) label.^[@CR13]^ Side effects in the olodaterol label were also included in the analysis; however, given the much shorter time that olodaterol has been available, the range of events is less extensive than for formoterol.

The list of labelled side effects in the formoterol Summary of Product Characteristics was used as a basis to determine safety search terms, as shown in Table [3](#Tab3){ref-type="table"}. Although not included in the formoterol label, nasopharyngitis was also evaluated in this analysis, as it was reported with olodaterol at a higher frequency than placebo in the clinical programme. While myocardial infarction is not included in the label for either formoterol or olodaterol, it was considered an important event for inclusion in this analysis. The formoterol-labelled events of bronchospasm paradoxical and taste disorders (dysgeusia) do not appear in the results as there were no occurrences in the study database in any treatment group. Events relating to hypersensitivity were not regarded typical to β~2~-agonist pharmacology but rather substance specific and, therefore, are not considered as part of the scope of this article.Table 3Label-recognised β~2~-agonist-related side-effect terms for formoterol and olodaterol^[@CR8],[@CR13]^ and database event search termsOrgan/body systemForadil^®^ (formoterol) SPC side effectsStriverdi^®^ Respimat^®^ (olodaterol) SPC side effectsStudy database event search terms (groups)CardiovascularTachycardia, cardiac arrhythmias e.g., atrial fibrillation, supraventricular tachycardia, extrasystoles--Tachyarrhythmias (including supraventricular and ventricular tachyarrhythmias) (SMQ)• Supraventricular tachyarrhythmias (SMQ)• Ventricular tachyarrhythmias (SMQ)Palpitations--Palpitations (PV)Angina pectoris--Ischaemic heart disease (SMQ)• Myocardial infarction (SMQ)• Other ischaemic heart disease (SMQ)Prolongation of QTc interval--Torsade de pointes/QT prolongation (SMQ)Increased blood pressure (including hypertension)HypertensionHypertension (SMQ)Variations in blood pressure--Hypotension (PV)Peripheral oedema--Peripheral oedema (PV)Respiratory and administration relatedBronchospasm, acute asthma exacerbation^a^--Bronchospasm (broad) (PV)Paradoxical bronchospasm--Bronchospasm paradoxical (PT)Throat irritation--Throat and other application site irritation (PV)Cough--Cough (PT)--NasopharyngitisNasopharyngitis (PT)GastrointestinalDry mouth--Dry mouth (PV)Nausea--Nausea (PV)MetabolicHypokalaemia--Hypokalaemia (PV)Hyperglycaemia--Hyperglycaemia/new--onset diabetes mellitus (SMQ)MusculoskeletalMyalgiaArthralgiaArthralgia/myalgia/muscle weakness (PV)Muscle cramp--Muscle spasm (PV)Nervous systemHeadache--Headache (PV)Tremor--Tremor (PV)DizzinessDizzinessDizziness (PV)Dysgeusia--Taste disorders (PV)PsychiatricAgitation--Restlessness/agitation (PV)Anxiety--Anxiety (PV)Nervousness--Nervousness (PV)Restlessness--Restlessness/agitation (PV)Insomnia--Insomnia (PV)*MedDRA* Medical Dictionary for Regulatory Activities, *PT* MedDRA preferred term, *PV* sponsor-defined pharmacovigilance end point, *SMQ* standardised MedDRA query^a^ Not specific to COPD indication, relates to bronchospasm (note: formoterol has an indication and label for both asthma and COPD)

Statistical methodology {#Sec16}
-----------------------

Descriptive statistics were provided for the incidence of AEs and aggregated AE groups (based on Medical Dictionary for Regulatory Activities SMQs, or sponsor-defined pharmacovigilance end points where SMQs were not available for the medical AE concept of interest). AE incidences are described with their crude incidence (percentage of patients with the event out of all patients in the treatment group) and exposure-adjusted incidence rate (number of events per 100 patient-years at risk with the drug) in order to adjust for different exposure between the treatment arms in case of differential study discontinuation. Exposure-adjusted RRs and their 95% CIs are calculated based on a Cochran--Mantel--Haenszel method stratified by study to compare olodaterol versus formoterol treatment groups. AEs of interest are displayed with their RR and 95% CI in a forest plot. Time to early discontinuation of patients from the study was compared with a Cox regression analysis of treatment effect using baseline long-acting muscarinic antagonist concomitant medication (tiotropium) use as a stratification factor. This is a post hoc analysis and no formal statistical testing of hypotheses was performed. The assessment of statistical significance via 95% CIs of the RR is, therefore, considered exploratory and no adjustment for multiple testing was done.

Data availability {#Sec17}
-----------------

Researchers can use the following link: <http://trials.boehringer-ingelheim.com> to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
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